If the SpaceX Stock Price Falls to $63, Here's What History Suggests Could Happen Next

SpaceX’s first earnings as a public company reported $7.8B Q2 revenue (+92% YoY), including AI revenue tripling to $2.6B and Starlink revenue rising 66% to $4.3B. However, heavy investment continued with capex increasing $2.8B to $18.4B, and the stock sold off more than 8% in after-hours despite CEO guidance that revenue could reach $1T by 2030. The article highlights a potential psychological support level around $63 if the stock follows a pattern similar to Meta’s IPO drawdown.

Analysis

The market is signaling that scale alone is not enough when capital intensity outruns visible free-cash-flow conversion. SPCX is being treated less like a hypergrowth compounder and more like an industrial buildout story, which means the multiple is vulnerable until management proves that incremental revenue can absorb the capex burden without continuous dilution or balance-sheet strain. That dynamic should also bleed into adjacent “AI infrastructure” names: suppliers can still benefit from the spend, but equity holders increasingly want evidence that the spend is funding a durable moat, not just a larger cost base.

The key second-order effect is on sentiment toward all capex-heavy growth franchises. If investors start applying the SPCX template to other high-spend tech stories, valuation support for names with long-dated payoff curves can compress over the next 1-3 months, even if fundamentals remain intact. NVDA is still the cleaner beneficiary because it monetizes the buildout directly, but the risk is that a broader “capex fatigue” trade makes the whole AI basket vulnerable on any miss or cautious guide.

Contrarian view: the consensus is using a Meta-IPO analogy that may be too forgiving. META had a fast path to ad monetization and operating leverage; SPCX looks more like a network-and-capex cycle where payback periods are much harder to underwrite. The thesis only breaks if management can show capex growth slowing while revenue keeps compounding, or if the company demonstrates a credible path to positive FCF within the next 2-4 quarters; otherwise any dip-buy is fighting the wrong business model.

Key Decisions for Investors

• Avoid chasing SPCX weakness today; wait for a 10-15% post-earnings bounce or for guidance that shows capex/revenue inflecting favorably before considering a long.
• If borrow/liquidity allows, initiate a tactical SPCX short or put spread on any relief rally over the next 2-6 weeks; thesis invalidates if management cuts capex growth or raises long-term FCF targets materially.
• Use any AI-capex sympathy selloff in NVDA to add exposure; the cleaner expression is supplier leverage to buildout spending, with a 1-3 month catalyst path tied to continued capex guidance across the ecosystem.
• Set a watch item on SPCX free-cash-flow trajectory for the next 1-2 earnings cycles; if FCF remains deeply negative while capex stays above revenue growth, multiple compression is likely to continue for 6-18 months.